# US 2010/0247554 A1 · Use of tam receptor inhibitors as antimicrobials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247554 A1
- Document ID: US20100247554A1
- Status: Published application
- Kind: A1
- Application number: 12/741,812
- Filed: 2008-11-07
- Published: 2010-09-30
- Earliest claimed: 2007-11-09
- Assignees: The Salk Institute for Biological Studies
- Inventors: Greg E. Lemke; John A.T. Young; Carla V. Rothlin; Suchita Bhattacharyya
- Web page: https://patentgrep.com/patent/US20100247554A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.

## Claims

### Claim 1

A method of enhancing a type I interferon (IFN) response against a pathogen in a subject, comprising:
administering to a subject infected with a pathogen a therapeutically effective amount of a TAM receptor inhibitor, thereby enhancing the type I interferon response against a pathogen in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TAM receptor is Tyro3, Axl, or Mer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the TAM receptor inhibitor is a small molecule inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the TAM receptor inhibitor binds to an intracellular kinase domain of the TAM receptor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the TAM receptor inhibitor binds to an extracellular domain of the TAM receptor, thereby interfering with the binding of Gas6 or Protein S to the TAM receptor and/or activation of the TAM receptor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the TAM receptor inhibitor comprises an antibody that binds to at least one of Gas6 or Protein S, thereby inhibiting the binding of Gas6 or Protein S to the TAM receptor and/or activation of the TAM receptor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the TAM receptor inhibitor has an IC50 of less than about 50 μM.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the TAM receptor inhibitor has a chemical structure of
wherein R is a hydrogen or methyl group.

### Claim 10 (depends on 1)

The method of claim 1, wherein the pathogen is a virus, a bacterium, or a parasite.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The method of claim 10, wherein the virus is human immunodeficiency virus (HIV), murine leukemia virus (MLV), Influenza, Yellow fever virus, West Nile virus, Arenavirus, Encephalitis virus, vesicular stomatitis virus (VSV), rhinovirus, HPV, respiratory syncytial virus, or coxsackievirus.

### Claim at position 13

-15. (canceled)

### Claim 16 (depends on 10)

The method of claim 10, wherein the bacterium is Listeria monocyotgenes or a mycobacterium.

### Claim 17

(canceled)

### Claim 18 (depends on 10)

The method of claim 10, wherein the parasite is Plasmodium or toxoplasma.

### Claim 19 (depends on 1)

The method of claim 1, wherein the type I interferon response is an increase in at least one of IFN-beta (IFN-β) production or IFN-alpha (IFN-α) production in macrophages, dendritic cells (DCs), fibroblasts, monocytes, or cardiomyocytes of the subject.

### Claim 20 (depends on 19)

The method of claim 19, further comprising measuring IFN-β production, IFN-α production or both in a macrophage.

### Claim 21 (depends on 1)

The method of claim 1, wherein the method is a method of treating a viral, bacterial, or parasitic infection in the subject.

### Claim 22

A method of treating a viral or bacterial infection in a subject, comprising:
administering to a subject infected with a virus or bacteria a therapeutically effective amount of a TAM receptor inhibitor, thereby treating the viral or bacterial infection.

### Claim 23

A method of screening for an antimicrobial agent, comprising:
contacting a cell expressing a TAM receptor with a test agent;
contacting the cell with a pathogen; and
measuring IFN-beta (IFN-β) production or IFN-alpha (IFN-α) production by the cell, wherein an increase in IFN-β or IFN-α production by the cell indicates that the test agent is an antimicrobial agent.

### Claim 24 (depends on 23)

The method of claim 23, further comprising:
determining whether contacting the cell with the test agent increases IFN-β or IFN-α production by the cell as compared to a control level of IFN-β or IFN-α production in the absence of the test agent; wherein an increase in IFN-β or IFN-α production by the cell in the presence of the test agent relative to the control level indicates that the test agent is an antimicrobial agent.

### Claim 25 (depends on 23)

The method of claim 23, further comprising:
measuring an interferon response factor (IRF) production by the cell, wherein an increase in IRF production by the cell indicates that the test agent is an antimicrobial agent.

### Claim at position 24

-30. (canceled)

### Claim 31 (depends on 10)

The method of claim 10 wherein the virus is not a filovirus.
